Aarti Drugs Limited — Investor Meet, 10-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Aarti Drugs reported Q3 FY26 consolidated revenue grew 8% YoY to INR602.9 Cr, but EBITDA declined 10% to INR56.3 Cr (9.3% margin) due to low utilization, weak antibiotic demand, and new facility ramp-up costs. PAT rose 58% to INR40.5 Cr. Management noted an encouraging January sales trend, anticipating 12-15% volume growth and 12-13% EBITDA margins in FY27, potentially reaching 14-15%. Key operational updates include Sayakha facility's smooth ramp-up (30% utilization in Q3, targeting 75% soon) and strong formulations exports. Future capex of INR150-200 Cr annually for 2 years targets metformin expansion, oncology, and CDMO. Management is confident in new capacities and strategic shifts driving profitability despite salicylic acid price pressures.